亿帆医药股份有限公司关于全资子公司参与全国药品集中采购拟中选的公告

Core Viewpoint - Company’s wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., has participated in the 11th national centralized drug procurement organized by the National Joint Procurement Office, with some products expected to be selected for this procurement [1][2]. Group 1: Product Information - The products proposed for selection include Ephedrine Hydrochloride Injection and Meprobamate Injection, which received drug registration certificates from the National Medical Products Administration in March 2023 and August 2024, respectively [2]. - The final prices and supply provinces for the selected products will be based on the data released by the Joint Procurement Office [1]. Group 2: Impact on the Company - The sales revenue from the proposed selected products currently accounts for a small proportion of the company's total revenue, and it is expected that there will be no significant impact on the company's performance in the short term [2]. - If the company successfully signs procurement contracts and implements them, it will enhance the accessibility of the products and improve the company's brand influence [2].